Lyell Immunopharma, Inc.LYELEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

Deep AnalysisCompare

Lyell Immunopharma, Inc. is a clinical-stage biotechnology company specializing in the research and development of next-generation chimeric antigen receptor (CAR) T cell therapies to treat various solid tumors. It primarily targets oncology patient segments across North America, focusing on addressing unmet medical needs in hard-to-treat cancer types.